<DOC>
	<DOCNO>NCT00024128</DOCNO>
	<brief_summary>RATIONALE : Donor peripheral stem cell transplantation may able replace immune cell destroy chemotherapy radiation therapy . Sometimes transplanted cell reject body 's normal tissue . Treatment donor white blood cell may prevent happen . PURPOSE : Phase II trial study effectiveness donor peripheral stem cell transplantation follow infusion donor white blood cell treat patient AIDS-related lymphoma .</brief_summary>
	<brief_title>Peripheral Stem Cell Transplantation Followed By Infusion White Blood Cells Treating Patients With AIDS-Related Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine response rate patient AIDS-related lymphoma treat allogeneic peripheral blood stem cell ( PBSC ) transplantation follow delay donor leukocyte infusion . - Determine complication rate patient treat PBSC transplantation . - Determine immune dysfunction recovery patient treat regimen . OUTLINE : This multicenter study . Patients receive cyclophosphamide IV 60 minute day -5 -3 . Patients receive prior mediastinal radiotherapy receive thymic radiotherapy day -1 . Allogeneic peripheral blood stem cell infuse day 0 . Patients also receive anti-thymocyte globulin IV 10-12 hour day -1 , 1 , 3 , 5 cyclosporine IV begin day -1 , switch oral possible , tapering day 35 . In absence active acute graft-versus-host disease ( GVHD ) , least 2 week completion cyclosporine , patient receive infusion donor leukocytes day 49 . Patients may receive second donor leukocyte infusion evidence persistent malignancy GVHD . Patients follow day 100 , day 120 , 180 , 270 , 365 , every 6 month thereafter . PROJECTED ACCRUAL : A total 12-35 patient accrue study within 3-4 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , AIDS-Related</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis Hodgkin 's disease nonHodgkin 's lymphoma Failed achieve complete remission initial therapy OR Relapsed initial therapy HIV1 seropositive Western Blot Measurable evaluable ( e.g. , pleural fluid involvement ) disease No leptomeningeal parenchymal CNS involvement active CNS leukemia HLAA , B , DR antigen match 1 antigen mismatch related donor available CD4 cell count great 100/mm3 ( initial 12 patient ) OR great 50/mm3 ( subsequent patient ) * HIV RNA le 110,000 copies/mL* NOTE : *Unless receive optimal antiretroviral therapy define current clinical standard PATIENT CHARACTERISTICS : Age : Physiologic 65 Performance status : Karnofsky 70100 % Life expectancy : Estimated diseasefree survival less 1 year Hematopoietic : See Disease Characteristics Hepatic : Bilirubin great 2 mg/dL Alkaline phosphatase great 3 time upper limit normal ( ULN ) * SGOT SGPT great 3 time ULN* Hepatitis B surface antigen negative NOTE : *Unless receive indinavir Renal : Creatinine great 1.5 mg/dL Creatinine clearance least 50 mL/min Cardiovascular : No symptomatic congestive heart failure No angina pectoris No uncontrolled hypertension LVEF least 45 % radionuclide ventriculography Pulmonary : No severe chronic obstructive lung disease No symptomatic restrictive lung disease DLCO great 50 % predict Other : No active uncontrolled infection No history cytomegalovirus retinitis pneumonitis , even treat No disease would limit life expectancy No symptomatic leukoencephalopathy No neuropsychiatric abnormality would preclude transplantation Human Tcell lymphotrophic virus ( HTLV1 ) antibody negative Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 3 month study PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : At least 1 week since prior chemotherapy Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : Not specify Other : No concurrent chronic suppressive therapy</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>AIDS-related peripheral/systemic lymphoma</keyword>
	<keyword>HIV-associated Hodgkin lymphoma</keyword>
</DOC>